On November 23, the opening ceremony of the 12th China Innovation and Entrepreneurship Competition Biopharmaceutical National Competition and the Summit Forum on the Development of the Big Health Industry were held in Taizhou, Jiangsu. The theme of this competition is "Innovation Leads, Entrepreneurship Builds Dreams". It aims to stimulate the enthusiasm for innovation among enterprises, support their technological innovation activities, create a strong engine to promote economic development and transformational upgrading, and empower high-quality economic and social development.

As the domestic technology innovation and entrepreneurship platform with the highest specifications, largest scale, and broadest influence, it gathers numerous resources for technological innovation and entrepreneurship. In the 12th China Innovation and Entrepreneurship Competition National Finals, HST won the title of National Excellent Enterprise for its project on highly efficient human-origin enriched fetal, pathogenic, and tumor nucleic acid technology. This achievement received unanimous affirmation from the competition's evaluation experts, further highlighting HST's innovative advantages in the industry.

In the current field of medical molecular diagnostics, NGS (Next-Generation Sequencing) is becoming increasingly important in applications such as unknown infections, eugenics, and tumor screening. However, in certain applications related to blood, such as NIPT (Non-Invasive Prenatal Testing), liquid biopsy, and pathogen metagenomic sequencing, many shortcomings are still evident. These hinder the rapid development of NGS, making the exploration of more efficient and simpler host interference removal techniques a direction for industry innovation. Against this technological backdrop, HST has independently innovated a dual-ion charge deviation biomolecular capture technology. By removing the interference from human hosts, they have developed a dual-ion bionic filter membrane paired with a low data volume sample analysis method, further promoting the innovative development of next-generation precision treatment technologies.

Established in 2022, Shenzhen Health SwifTech Co., Ltd. is an innovative high-tech enterprise dedicated to the research and development and application of advanced molecular diagnostics fields such as efficient host removal. It provides customers with excellent host interference removal system solutions, promotes the realization of precise diagnosis through low data volume methods, integrates advantages in research, production, management, and services, explores the field of cellular technology, and is committed to promoting the innovative development of next-generation precision treatment technologies.